S1316

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction (MBO)

A study for patients with intra-abdominal cancer with clinical evidence of bowel obstruction

If you have a patient with a malignant bowel obstruction (MBO) please consider this important study to assess non-surgical vs. surgical treatment options

- Patients must be candidates for surgery.
- Patient must not have signs of "acute" abdomen.
- Patients must be registered to the study within 3 working days after surgical consult for MBO or within 3 working days after treatments to make them eligible for surgery (whichever is later). Treatment is defined as any medication or invasive interventions beyond nasogastric decompression, hydration, pain medications, or antiemetics.
- Performance Status of 0-2 within 7 days prior to hospitalization.
- \geq 18 years of age; ability to speak/read English or Spanish.

Study Design and Procedures

Patients should be offered randomization at screening. If patients choose not to be randomized, they may be offered non-randomized surgical management (the non-surgical management arm was closed with Revision #12). Surgeon must have equipoise for the benefit of surgery, even if patient chooses not to be randomized.

For more information about S1316, please take a tab below:

| S1316 |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |